Document:

Exhibit 10.16

 

CANOO INC.

 

EXECUTIVE EMPLOYMENT AGREEMENT

for

Ulrich Kranz

 

This Executive Employment
Agreement (“Agreement”) is entered into by and between Ulrich Kranz (the “Executive”)
and Canoo Inc., a Delaware company incorporated under the laws of Delaware (the “Company”).

 

Whereas,
the Company values the Executive as a critical leader in Company’s organization and desires to continue to employ the Executive
to provide services to the Company;

 

Whereas,
the Company wishes to provide the Executive with certain compensation and benefits in return for the Executive’s continued
services as set forth in this Agreement; and

 

Whereas,
the Executive wishes to continue to be employed by the Company and provide services to the Company in return for certain compensation
and benefits as set forth in this Agreement;

 

Now,
Therefore, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between
the parties hereto as follows:

 

1. Employment
by the Company.

 

1.1 Effective
Date. The effective date (“Effective Date”) of all terms in this Agreement shall be October 19, 2020.
The terms of this Agreement shall supersede and restate the offer letter by and between Company and the Executive dated as of November
6, 2018, effective as of the Effective Date.

 

1.2 Position.
The Company agrees to employ the Executive in the positions of Chief Executive Officer and Special Advisor to the Executive Chairman
and the Executive hereby accepts employment in such ongoing capacity. In the event that the Company ceases to have an Executive
Chairman, the Executive Chairman or the Board shall determine the person or body to whom the Executive shall serve as Special Advisor
and the Executive’s title shall be adjusted accordingly (and all references herein to the title “Special Advisor to
the Executive Chairman” shall be deemed to defer to such successor title). Upon the appointment of a new Chief Executive
Officer of the Company, the Executive shall cease to serve as Chief Executive Officer but shall continue to serve as Special Advisor
to the Executive Chairman. During the Executive’s employment with the Company, the Executive will devote the Executive’s
best efforts and substantially all of the Executive’s business time and attention to the business of the Company, except
for periods of flexible paid time off and reasonable periods of illness or other incapacities permitted by the Company’s
Flexible Paid Time Off Policy in the Company Handbook or in the Company’s other general employment policies (collectively,
“Employment Policies.”) The Executive will report to the Board of Directors (the “Board”)
of the Company’s parent holding company, Canoo Holdings Ltd. (“Parent”). The Company reserves the
right to change the Executive’s position, duties, and work location, from time to time in its discretion.

 

    1

     

    

 

1.3 Duties.
The Executive shall serve in an executive capacity and shall perform the customary duties of the Executive’s positions, such
duties as are assigned to the Executive from time to time by the Board, consistent with the Bylaws and Employment Policies of the
Company, and as required by the Board.

 

1.4 Location.
The Executive’s primary office location shall be Torrance, California. The Company reserves the right to reasonably require
the Executive to perform the Executive’s duties at places other than its corporate headquarters from time to time, and to
require reasonable business travel, including international travel.

 

1.5 Policies
and Procedures. The employment relationship between the parties shall also be governed by the Employment Policies and practices
of the Company, including those relating to protection of confidential information and assignment of inventions, except that when
the terms of this Agreement differ from or are in conflict with the Company’s Employment Policies, this Agreement shall control.

 

1.6 Board of
Directors. The Executive acknowledges that the Executive has been appointed to the Board and the Executive agrees to
serve as a director of the Company. The Executive agrees that in the event the Executive’s employment with the Company
is terminated for any reason, either voluntarily or involuntarily, with or without Cause, or if the Executive ceases to serve
as Chief Executive Officer, the Executive shall resign the Executive’s position as a member of the Board simultaneously
with the earlier of: (a) Executive’s ceasing to serve as Chief Executive Officer, or (b) the termination of the
Executive’s employment.

 

1.7 Corporate
References Following Transaction Close. Prior to the Effective Date, the Company and Parent entered into that Merger Agreement
and Plan of Reorganization dated August 17, 2020, with HCAC IV First Merger Sub, Ltd., an exempted company incorporated with limited
liability in the Cayman Islands and HCAC IV Second Merger Sub, LLC, a Delaware limited liability company (the “Merger
Agreement”), a copy of which has been provided to the Executive. Provided the transactions contemplated by the Merger
Agreement are successfully closed, the following references throughout this Agreement shall be automatically changed, as indicated,
effective immediately upon such closing date: (i) “Company” shall refer to Canoo Technology Inc., a Delaware company
incorporated under the laws of Delaware, the contemplated surviving employer entity of the Executive; (ii) “Canoo Holdings
Ltd.” shall refer to Canoo Technologies Inc., a Delaware company incorporated under the laws of Delaware, as the contemplated
surviving public parent company (the “new public parent company”); and (iii) the “Board” shall refer to
the new Board of Directors empaneled for the new public parent company. Notwithstanding the foregoing, and for the avoidance of
doubt, should the transactions contemplated by the Merger Agreement not close as anticipated, all such references shall remain
unchanged and this Agreement shall continue in full force and effect.

 

2. Compensation
and Benefits.

 

2.1 Salary.
During such time as the Executive is Chief Executive Officer of the Company, the Executive shall receive for services to be rendered
hereunder a monthly base salary of $54,000 ($648,000 annualized) (as such amount may be increased from time to time pursuant to
the subsequent provisions of this Section 2.1, the “Base Salary”), subject to applicable withholdings
and deductions, as of the Effective Date. The Base Salary shall be reviewed annually and may be increased as approved by the Board
(or any authorized committee thereof). At such time, if any, that the Executive is no longer Chief Executive Officer but continues
employment hereunder (the date, if any, that such change occurs, the “Title Change Date”), then, for
a period of two years following the Title Change Date (or, if earlier, the date on which the Executive ceases to be employed hereunder,
except as expressly provided otherwise in Section 6.3(i)), and subject to compliance with Section 4.3 hereof, the Executive shall
be paid Base Salary at an annual rate of $2,500,000, with such amounts to be paid in equal monthly installments, subject to applicable
withholdings and deductions.

 

    2

     

    

 

2.2 Benefits.
The Executive shall be entitled to all rights and benefits for which the Executive is eligible under the terms and conditions of
the standard Company benefits and compensation practices which may be in effect from time to time and provided by the Company to
its employees generally, in each case at levels and in amounts, and under terms and conditions, at least commensurate with plans
offered to similarly situated employees by the Company from time to time. The Company may change employee benefits from time to
time in its discretion.

 

2.3 Restricted
Share Awards. 

 

(i) As
of the Effective Date, the Executive has purchased 2,865,800 restricted Ordinary Shares of Parent pursuant to restricted share
purchase agreements entered into with Parent, as scheduled in Appendix I to this Agreement (the “Executive Restricted
Shares”). As of the Effective Date, 1,014,968 of the Executive Restricted Shares were fully vested and held by the
Executive absent any risk of forfeiture (the “Vested Restricted Shares”) and 1,850,832 of the Executive
Restricted Shares remain subject to vesting restrictions (the “Unvested Restricted Shares”). As of the
Effective Date, the Company will re-purchase the Unvested Restricted Shares at a re-purchase price per share equal to the purchase
price per share paid by the Executive for each Unvested Restricted Share.

 

Prior to the consummation
of the transactions contemplated by the Merger Agreement, the Executive will enter into a lock-up agreement, the form of which
is provided as Exhibit B to the Merger Agreement, and such agreement will apply to the Vested Restricted Shares (the “Lock-Up
Agreement”). The Lock-Up Agreement, including any Lock-Up Period (as defined in the Lock-Up Agreement) will remain
in full force and effect until the expiration of the effectiveness of the Lock-Up Agreement, pursuant to the terms and conditions
contained therein.

 

2.4 Business
Expenses. The Company will pay or reimburse the Executive for all reasonable business expenses incurred or paid by the Executive
in the performance of the Executive’s duties and responsibilities for the Company in accordance with the Company’s
Expense Reimbursement Policy, which have been made available to the Executive.

 

2.5 Waiver
of Preemptive Rights. Subject to and effective immediately prior to the consummation of the transactions contemplated by the
Merger Agreement, the Executive shall permanently and irrevocably waive certain preemptive rights to which the Executive is entitled
pursuant to Section 5.1 of that certain Amended and Restated Voting and Preemptive Rights Agreement dated as of March 4, 2019,
by and among the Company, the Executive and certain other shareholders of the Company party thereto, as amended and to subject
Ordinary Shares held by the Executive to certain Lock-Up Periods as provided in this Agreement.

 

3. Proprietary
Information Obligations.

 

3.1 Agreement.
As a condition of the Executive’s ongoing employment, the Executive hereby reaffirms and agrees to continue to abide by the
Employee Confidential Information and Invention Assignment Agreement dated December 27, 2017, attached hereto as Exhibit A.
Notwithstanding anything in this Agreement or the Employee Confidential Information and Invention Assignment Agreement to the contrary,
the Executive understands that nothing contained in this Agreement limits his ability to report possible violations of law or regulation
to or file a charge or complaint with the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the
National Labor Relations Board, the Occupational Safety and Health Administration, the Department of Justice, the Congress, any
Inspector General, or any other federal, state or local governmental agency or commission or regulatory authority (collectively,
“Government Agencies”). The Executive further understands that this Agreement does not limit his ability to
communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any
Government Agency, including providing documents or other information, without notice to the Company.

 

    3

     

    

 

3.2 Third
Party Agreements and Information. The Executive represents and warrants that the Executive’s employment by the Company
will not conflict with any prior employment or consulting agreement or other agreement with any third party, and that the Executive
will perform the Executive’s duties to the Company without violating any such agreement. The Executive represents and warrants
that the Executive may not use or disclose confidential information arising out of prior employment, consulting, or other third
party relationships in connection with the Executive’s employment by the Company, except as expressly authorized by that
third party. During the Executive’s employment by the Company, the Executive will use in the performance of the Executive’s
duties only information that is generally known and used by persons with training and experience comparable to the Executive’s
own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by the
Executive in the course of the Executive’s work for the Company (it being acknowledged and agreed by the Company that the
Executive’s use of the Executive’s know-how, expertise, experience or skills shall not constitute a breach of this
Section 3.2).

 

4. Outside
Activities During Employment.

 

4.1 Exclusive
Employment. Except with the prior written consent of the Board, the Executive will not during employment with the Company undertake
or engage in any other employment, occupation or business enterprise, other than ones in which the Executive is a passive investor.
The Executive may engage in civic and not-for-profit activities, and conduct the activities set forth on Schedule A,
so long as such activities do not materially interfere with the performance of the Executive’s duties hereunder. For the
avoidance of doubt, the Executive shall not become a director of any for-profit entity without first receiving the approval of
the Board, which shall not be unreasonably withheld.

 

4.2 No
Adverse Interests. Except as permitted by Section 4.3, the Executive agrees, during the Executive’s employment with
the Company, not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the
Executive to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.

 

4.3 Noncompetition.
During the Executive’s employment by the Company, except on behalf of the Company and its affiliates, the Executive will
not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant,
or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with
any other person, corporation, firm, partnership or other entity whatsoever which were known by the Executive to compete directly
with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company; provided,
however, that anything above to the contrary notwithstanding, the Executive may own, as a passive investor, securities of any
competitor corporation, so long as the Executive’s direct holdings in any one such corporation shall not in the aggregate
constitute more than one percent (1%) of the voting stock of such corporation pursuant to any direct or indirect interest held
by the Executive or the Executive’s affiliates in any venture capital, private equity or similar investment fund or entity.

 

    4

     

    

 

5. Noninterference.
While employed by the Company the Executive agrees not to interfere with the business of the Company by directly or indirectly:
(a) soliciting, attempting to solicit, inducing, or otherwise causing any employee of the Company, with whom the Executive worked
while employed by the Company, to terminate employment in order to become an employee, consultant or independent contractor to
or for any other person or entity; or (b) soliciting the business of any customer of the Company which at the time of the solicitation,
or during the year immediately prior thereto, was listed on the Company’s customer list (it being acknowledged and agreed
that the Executive’s performance of the Executive’s duties hereunder shall not constitute a breach of this Section
5).

 

6. Termination
Of Employment.

 

6.1 At-Will
Relationship. The Executive’s employment relationship is at-will. Either the Executive or the Company may terminate the
employment relationship at any time, with or without Cause, as defined below, upon advance written notice.

 

6.2 Wage
Payments upon Termination. Upon termination of the Executive’s employment for any reason, the Executive shall be paid
all accrued but unpaid Base Salary (“Accrued Salary”).

 

6.3 Termination
without Cause or for Good Reason.

 

(i) Upon
termination of the Executive’s employment by the Company without Cause or by the Executive for Good Reason (either, a “Qualifying
Termination”), the Executive will receive the Accrued Salary. In addition, upon a Qualifying Termination, subject
to the Executive’s fulfillment of the Release Obligation, as defined below, the Executive shall be entitled to receive severance
payments as follows: (a) if such Qualifying Termination occurs prior to the Title Change Date (and, for the avoidance doubt, the
Executive is also not provided with the opportunity to continue in his role as Special Advisor to the Executive Chairman), in an
aggregate amount equal to $5,000,000; and (b) if such Qualifying Termination occurs on or after the Title Change Date and prior
to the second (2nd) anniversary of the Title Change Date, in an aggregate amount equal to $5,000,000 less any Base Salary
payments made between the Title Change Date and the date of the Qualifying Termination (as applicable in clause (a) or (b), the
“Severance Payments”). In each case of clause (a) and (b), the Severance Payments shall be paid in equal
monthly installments, subject to applicable withholdings and deductions, with the first installment being paid on the sixtieth
(60th) day following the Executive’s Qualifying Termination, subject to Section 6.7(i), and the final installment
being paid on, or within thirty (30) days following, the second anniversary of the date of the Qualifying Termination (in the case
of clause (a)) or the second anniversary of the Title Change Date (in the case of clause (b)).

 

(ii) If
at the time of the Executive’s Qualifying Termination the Executive participates in health care coverage through the Company’s
plan, then provided that the Executive fulfills the Release Obligation, and timely elects continued coverage under COBRA, the Company
will pay the Executive’s COBRA premiums to continue the Executive’s coverage (including coverage for eligible dependents,
if applicable) (“COBRA Premiums”) through the period (the “COBRA Premium Period”)
starting on the termination date and ending on the earliest to occur of the date: (a) three (3) months after the termination date;
(b) the Executive becomes eligible for group health insurance coverage through a new employer; or (c) the Executive ceases to be
eligible for COBRA continuation coverage for any reason, including plan termination. In the event the Executive becomes covered
under another employer’s group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period,
the Executive must promptly notify the Company of such event.

 

    5

     

    

 

(iii) If
the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without a substantial risk of violating applicable
law (including, without limitation, Section 2716 of the Public Health Service Act), the Company instead shall pay to the Executive,
on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including
premiums for the Executive and the Executive’s eligible dependents who have elected and remain enrolled in such COBRA coverage),
subject to applicable tax withholdings (such amount, the “Special Cash Payment”), for the remainder of
the COBRA Premium Period. The Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.
Subject to Section 6.7, on the sixtieth (60th) day following the Executive’s termination date, the Company will
make the first payment to the Executive under this paragraph, in a lump sum, equal to the aggregate Special Cash Payments that
the Company would have paid to the Executive through such date, had the Special Cash Payments commenced on the first day of the
first calendar month following the termination date through such sixtieth (60th) day, with the balance of the Special
Cash Payments paid thereafter on the schedule described above

 

6.4 Termination
for Cause. Upon termination of the Executive’s employment for Cause the Executive will only receive the Accrued Salary.

 

6.5 Termination
Due to Death or Disability. Upon termination of the Executive’s employment due to the Executive’s death or Disability,
as defined below, the Executive (or the Executive’s estate) will receive the Accrued Salary.

 

6.6 Definitions.
For purposes of this Agreement, the following definitions shall apply:

 

(i) “Cause”
means: (a) the Executive’s conviction or plea of guilty or nolo contendere in a court of law of a felony or a conviction
or plea of guilty or nolo contendere for any crime involving an act of moral turpitude, fraud or dishonesty or any conduct
by the Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its
subsidiaries and affiliates if the Executive were retained in the Executive’s position; (b) a good faith determination by
the Board of Directors that the Executive has engaged in acts of willful fraud, breach of fiduciary duty, and/or breach of the
Executive’s duty of loyalty to the Company or any of its parent or subsidiary entities, in any such case, which is materially
injurious to the Company or any of its parent or subsidiary entities; or (c) the Executive’s (A) material breach of this
Agreement, the Company’s Confidential Information and Invention Assignment Agreement and any other of the Company’s
lawful policies that have been provided to the Executive in writing or otherwise made available to the Executive through the Company’s
intranet, which breach is materially injurious to the Company or any of its parent or subsidiary entities and/or (B) willful and
continued failure or refusal to substantially perform the Executive’s duties to the Company; provided, however, that no termination
shall be deemed for Cause under Section 6.6(i) unless the Executive has first received written notice from the Board of Directors
advising the Executive of the specific acts or omissions alleged to constitute a violation, failure, and/or breach as set forth
in this Section 6.6(i) and the Executive shall have failed to correct the acts or omissions so complained of to the good faith
satisfaction of the Board within thirty (30) days thereafter.

 

    6

     

    

 

(ii) “Good
Reason” means (unless the Executive has expressly agreed to such event in a signed writing): (a) a reduction in the
Executive’s current Base Salary of ten percent (10%) or more unless such reduction is part of a generalized salary reduction
affecting all of the executive officers of the Company; (b) a material diminution in the Executive’s authority, duties, or
responsibilities; (c) a material change in the geographic location at which the Executive must perform services; or (d) the Company’s
material breach of the terms of the Executive’s employment as set forth in this Agreement. No termination by the Executive
shall constitute a termination for Good Reason unless the Executive gives the Company notice of the condition constituting Good
Reason within thirty (30) days following the initial occurrence thereof (such notice must be signed by the Executive, specifically
identify the alleged breach and specifically refer to this Section 6.6(ii)), the Company does not remedy the condition within forty-five
(45) days of receiving such notice, and the Executive actually terminates the Executive’s employment within thirty (30) days
following the expiration of the Company’s cure period. For the avoidance of doubt, the Executive ceasing to serve as Chief
Executive Officer, but continuing to serve as Special Advisor to the Executive Chairman, shall not constitute Good Reason.

 

(iii) “Disability”
means the Executive is unable to engage in any substantial gainful activity due to any medically determinable physical or mental
impairment that can be expected to last for a continuous period of not less than twelve (12) months, which condition is verified
by a physician, mutually agreed to by the Executive and the Company, that is licensed to practice medicine in the State of California.

 

(iv) “Release
Obligation” means that: (a) the Executive has signed a termination agreement that will be presented to the Executive
before the termination date, and which includes a general release and waiver of claims and certain nondisparagement provisions
and restrictive covenants in favor of the Company and its affiliates based on the form attached as Exhibit B hereto,
and (b) the Executive has allowed the release and waiver to become fully effective without revocation during any applicable revocation
period, provided that in all cases, the release and waiver shall become effective no later than the 60th day following the termination
date.

 

6.7 Sections
409A and 280G.

 

(i) Section
409A. The payments and benefits under this Agreement are intended to qualify for exemptions from the application of Section
409A of the Internal Revenue Code of 1986, as amended, and the rules and regulations thereunder (collectively, “Section
409A”), and this Agreement will be construed to the greatest extent possible as consistent with those provisions,
and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with
Section 409A to the extent necessary to avoid adverse taxation under Section 409A. Notwithstanding anything to the contrary herein,
to the extent required to avoid adverse taxation under Section 409A, a termination of employment shall not be deemed to have occurred
for purposes of any provision of this Agreement providing for the payment of amounts or benefits upon or following a termination
of employment unless such termination is also a “separation from service” within the meaning of Section 409A. The Executive's
right to receive any installment payments will be treated as a right to receive a series of separate payments and, accordingly,
each installment payment shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the
contrary in this Agreement, if the Executive is deemed by the Company at the time of the Executive's separation from service to
be a “specified employee” for purposes of Section 409A, and if any of the payments upon separation from service set
forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation,” then, to the
extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Section
409A and the related adverse taxation under Section 409A, such payments shall not be provided to the Executive prior to the earliest
of (a) the expiration of the six-month period measured from the date of separation from service, (b) the date of the Executive's
death or (c) such earlier date as permitted under Section 409A without the imposition of adverse taxation. With respect to payments
to be made upon execution of an effective release, if the release revocation period spans two calendar years, payments will be
made in the second of the two calendar years to the extent necessary to avoid adverse taxation under Section 409A. With respect
to reimbursements or in-kind benefits provided to the Executive hereunder (or otherwise) that are not exempt from Section 409A,
the following rules shall apply: (x) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any
one of the Executive’s taxable years shall not affect the expenses eligible for reimbursement, or in-kind benefit to be provided
in any other taxable year, (y) in the case of any reimbursements of eligible expenses, reimbursement shall be made on or before
the last day of the Executive’s taxable year following the taxable year in which the expense was incurred and (z) the right
to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

 

    7

     

    

 

(ii) Section
280G.

 

(A) If
any payment or benefit the Executive will or may receive from the Company or any of its affiliates under this Agreement or otherwise
(a “280G Payment”) would (x) constitute a “parachute payment” within the meaning of Section
280G of the Internal Revenue Code of 1986, as amended, and the rules and regulations thereunder (the “Code”),
and (y) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”),
then each such 280G Payment (collectively, the “Payments”) shall be reduced to the extent necessary for
the Payments to equal, in the aggregate, the Reduced Amount. The “Reduced Amount” shall be either (1)
the largest portion of the Payments that would result in no Excise Tax on the Payments (after reduction), or (2) the total Payments,
whichever amount (i.e., the amount determined by clause (1) or by clause (2)), after taking into account all applicable
federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate),
results in the Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some
portion of the Payments may be subject to the Excise Tax. If a reduction in the Payments is required pursuant to the preceding
sentence and the Reduced Amount is determined pursuant to clause (1) of the preceding sentence, the reduction shall occur in the
manner (the “Reduction Method”) that results in the greatest economic benefit for the Executive. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro
Rata Reduction Method”).

 

(B) Notwithstanding
any provision of Section 6.7(ii)(A) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would cause
any portion of the Payments to be subject to taxes pursuant to Section 409A, and any state law of similar effect that would not
otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the
case may be, shall be modified so as to avoid the imposition of taxes pursuant to Code Section 409A as follows: (x) as a first
priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for the Executive as determined
on an after-tax basis; (y) as a second priority, Payments that are contingent on future events shall be reduced (or eliminated)
before Payments that are not contingent on future events; and (z) as a third priority, Payments that are “deferred compensation”
within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the
meaning of Section 409A, with any payments subject to Section 409A reduced in the reverse order in which such Payments would be
paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary,
through to such payment or benefit that would be made first in time).

 

    8

     

    

 

(C) The
Company shall determine the accounting, law or consulting firm to make the determinations required by this Section 6.7(ii)
and shall bear all expenses with respect to such determinations.

 

(D) If
the Executive receives any Payments for which the Reduced Amount was determined pursuant to clause (1) of Section 6.7(ii)(A)
above and the Internal Revenue Service determines thereafter that some portion of the Payments is subject to the Excise Tax, the
Executive agrees to promptly return to the Company a sufficient amount of the Payments (after reduction pursuant to clause (1)
of Section 6.7(ii)(A) above so that no portion of the remaining Payments is subject to the Excise Tax). For the avoidance
of doubt, if the Reduced Amount was determined pursuant to clause (2) of Section 6.7(ii)(A) above, the Executive shall have
no obligation to return any portion of the Payments pursuant to the preceding sentence.

 

7. Cooperation
with Company.

 

7.1 Cooperation
Obligation. During and after the Executive’s employment, the Executive will cooperate with the Company in responding
to the reasonable requests of the Company’s Chairman of the Board, Chief Executive Officer, or General Counsel, in connection
with any and all existing or future litigation, arbitrations, mediations or investigations brought by or against the Company, or
its affiliates, agents, officers, directors or employees, whether administrative, civil or criminal in nature, in which the Company
reasonably deems the Executive’s cooperation necessary or desirable. In such matters, the Executive agrees to provide the
Company with reasonable advice, assistance, and information, including offering and explaining evidence, providing sworn statements,
and participating in discovery and trial preparation and testimony. The Executive also agrees to promptly send the Company copies
of all correspondence (for example, but not limited to, subpoenas) received by the Executive in connection with any such legal
proceedings, unless the Executive is expressly prohibited by law from so doing.

 

7.2 Expenses
and Fees. The Company will reimburse the Executive for reasonable out-of-pocket expenses actually incurred by the Executive
as a result of the Executive’s cooperation with the obligations described in Section 7.1, in accordance with the Company’s
Expense Reimbursement Policy.

 

8. Effect
of Breach. In the event of the Executive’s material breach of this Agreement, including Exhibit A and Exhibit
B, the Executive shall forfeit any unpaid Severance Payments, and unpaid COBRA Premiums or Special Cash Payments (as the case
may be). In addition to any other remedies at law or equity that the Company may have, the Company shall have the right to withhold
any unpaid Severance Payments, unpaid COBRA Premiums or Special Cash Payments (as the case may be), upon the Company’s written
notice to the Executive of a good faith reasonable belief that the Executive has breached this Agreement, including Exhibit
A and Exhibit B.

 

9. Dispute
Resolution.

 

9.1 To
ensure the rapid and economical resolution of disputes that may arise in connection with the Executive’s employment with
the Company, the Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including
but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this
Agreement, the Executive’s employment with the Company, or the termination of the Executive’s employment, shall be
resolved pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by law, by final, binding
and confidential arbitration conducted by JAMS or its successor, under JAMS’ then applicable rules and procedures for employment
disputes before a single arbitrator (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/),
in Los Angeles (Century City), California. The Executive acknowledges that by agreeing to this arbitration procedure, both the
Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.

 

    9

     

    

 

9.2 All
claims, disputes, or causes of action under this arbitration agreement, whether by the Executive or the Company, must be brought
in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative
proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims
of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that
the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable,
any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.

 

9.3 This
arbitration agreement shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law,
including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the
California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are
not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the
Federal Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event the
Executive intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed
with a court, while any other claims will remain subject to mandatory arbitration. The Executive will have the right to be represented
by legal counsel at any arbitration proceeding.

 

9.4 Questions
of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions
which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall: (a)
have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be
permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief,
if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which
the award is based. The arbitrator shall be authorized to award all relief that the Executive or the Company would be entitled
to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that the Executive
would be required to pay if the dispute were decided in a court of law. Nothing in this arbitration agreement is intended to prevent
either the Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion
of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and
state courts of any competent jurisdiction.

 

10. Indemnification.

 

10.1 Definitions.
For purposes of this Section 10, the following terms shall have the following meanings:

 

“Action”
means any civil, criminal, administrative, or regulatory action, arbitration, claim, demand, investigation, litigation, mediation,
proceeding, or suit, in each instance, of whatever nature, known or unknown, liquidated or unliquidated.

 

    10

     

    

 

“Company
Action”, means any Action that directly or indirectly involves the Executive, or with which the Executive may be
threatened, in each instance relating to or arising from or out of the business and affairs of the Company or its affiliates.

 

“Prior Employer
Action”, means any Action that directly or indirectly involves the Executive, or with which the Executive may be
threatened, in each instance relating to, or arising from our out of (i) any act or omission by the Executive, regardless of when
taken (or failed to be taken) to the extent any such act or omission directly or indirectly benefitted (or was anticipated or expected
by the Executive, Parent and/or the Company to benefit, and/or was alleged to have benefitted) Parent, the Company or their affiliates,
or (ii) any act or omission by the Executive in connection with the Executive’s anticipated, expected, or actual employment
with Parent, the Company, or their affiliates to the extent such act or omission directly or indirectly benefitted (or was anticipated
or expected by the Executive, Parent, and/or the Company to benefit, and/or was alleged to have benefitted) Parent, the Company,
or their affiliates. By way of example only, any action by the Executive’s immediately preceding employer and any related
or required counterclaims ( e.g., breach of a confidentiality agreement, breach of a non-competition agreement, breach of a non-solicitation
agreement, breach of the duty of loyalty, breach of fiduciary duty, unfair competition, misappropriation of trade secret, misappropriation
of confidential information, or other claims relating in any way to the Executive’s former employment) shall be included
as a Prior Employer Action. By further way of example only, a Prior Employer Action includes an Action involving Executive’s
immediately preceding employer alleging, among others a breach of a non-solicitation arrangement or agreement, or a breach of a
confidentiality arrangement or agreement.

 

“Liability”
means any claim, cost (including but not limited to attorneys’ fees), damage, debt, demand, expense, liability, loss, or
obligation, in each instance, whether incurred, known or unknown, asserted or unasserted, determined or determinable, absolute
or contingent, accrued or unaccrued, liquidated or unliquidated, incurred, paid or payable, in each instance whether in connection
with the satisfaction of any defense, disposition, judgment, settlement, award, or compromise.

 

“Prior Employer
Covered Claims” means any Action or Liability brought by, or directly or indirectly involving or relating to, or
arising from, the Executive’s previous employer, or any of the Executive’s prior employer’s shareholders, officers,
successors or assigns, whether relating to the Executive’s duties as an employee or otherwise, to the extent such Action
or Liability is fully covered and actually paid by an insurance policy (e.g., D&O insurance previously purchased by
such prior employer) for which the Executive are included as an insured or additional insured.

 

10.2 Company
Action. Parent and the Company shall, to the fullest extent permitted by law, indemnify, defend, hold harmless, and release
the Executive for, from, and against all Liabilities arising from any Company Action, other than any Company Action which is finally
determined (whether by admission in a settlement or as determined by a final, non-appealable judgment by a court of competent jurisdiction)
to have resulted from (a) an act of fraud perpetrated by the Executive against Parent or the Company, (b) the Executive’s
gross negligence or willful misconduct in the performance of the Executive’s duties towards Parent or the Company or (c)
an act of the Executive’s resulting in a conviction or plea of guilty or nolo contendere for any crime involving an
act of moral turpitude, fraud or dishonesty.

 

10.3 Prior
Employer Action. Except to the extent covered as a Prior Employer Covered Claim, Parent and the Company shall, to the fullest
extent permitted by law, indemnify, hold harmless, and release the Executive for, from and against all Liabilities arising from
any Prior Employer Action.

 

    11

     

    

 

10.4 General.
Any right to indemnification the Executive may have pursuant to this Section 10 shall be cumulative with, and in addition to, any
and all rights to which the Executive may otherwise be entitled, and shall extend to the Executive’s heirs, successors, and
assigns. In any such Action, the Executive shall have the right to engage, at the Company’s reasonable expense, separate
counsel of the Executive’s own choice. Any amounts payable to the Executive pursuant to this Section 10 shall be increased
such that (i) after the Executive pay any taxes on the amounts received by the Executive pursuant to this Section 10, and (ii)
after the Executive pays any Liabilities relating to such Action, the Executive shall not be in a worse position than the Executive
would have been had such Action never commenced.

 

10.5 Cooperation.

 

(i) In
the course or pursuit of the resolution, negotiation, or settlement with respect to an Action for which the Executive may be indemnified
pursuant to this Section 10, the Executive, Parent and the Company will:

 

(A) reasonably
cooperate with one another in diligently and actively pursuing the defense or settlement of such Action,

 

(B) permit
the other to participate in all decision making and other aspects of such Action,

 

(C) keep
each other fully informed regarding the status and progress of such Action,

 

(D) provide
copies of written communications relating to such Action, and

 

(E) not
settle such Action without the prior written consent of the other, which consent shall not be unreasonably withheld, conditioned,
or delayed.

 

(ii) As
an example of a matter falling within the parameters of Section 10.5(i)(E), neither Parent nor the Company may settle a Prior Employer
Claim without the Executive’s prior written consent, not to be unreasonably withheld, if such settlement: (a) includes a
concession, stipulation, or admission that the Executive engaged in any fraud, misconduct, or gross negligence or could otherwise
reasonably be expected to cause damage to the Executive’s reputation, or hinder the Executive’s reasonable prospects
for future employment, (b) other than as contemplated in the immediately preceding clause (a), imposes any restriction or injunction
on, or any liability to the Executive, and/or (c) fails to include a general release of all claims. Whether a consent is unreasonably
withheld by the Executive shall be determined in light of, among others, the legitimate interests of the Company having an interest
to settle the Company’s matters related to such an Action, rather than solely the Executive’s financial interest in
such settlement.

 

(iii) Notwithstanding
anything in Section 10.5(ii) to the contrary, if the Executive (a) unreasonably withhold the Executive’s consent to a global
and comprehensive settlement of a Prior Employer Action, and (b) the Executive is fully indemnified by Parent or the Company respecting
any monetary damages arising from, or relating to such settlement, then Parent and the Company may (x) settle the Company’s
interests in such Action without the Executive’s consent, (y) request reimbursement of all expenses (including attorneys’
fees) that were previously paid by the Company in defense of such Action and (z) may elect to no longer be responsible for any
further indemnification obligations respecting such Action.

 

    12

     

    

 

10.6 Matters
Involving the Company.

 

(i) If
the Company, or its affiliates becomes a party to any Action that may give rise to a Liability pursuant to this Section 10, then:

 

(A) the
Company shall give written notice to the Executive respecting such matter; and

 

(B) the
Company and its affiliates, shall keep the Executive and the Executive’s counsel reasonably and timely informed of all developments
relating to such Action, and shall timely provide the Executive and the Executive’s counsel with copies of all material correspondence
with respect thereto.

 

(ii) If
the Company, or its affiliates, are or become involved in any matter relating, directly or indirectly, with an Action, the Company,
and its affiliates shall not settle, compromise, enter into any arrangement relating to the resolution of such matter, agree to
or accept any finding relating thereto, or enter into any obligation or arrangement unless such settlement, compromise, arrangement,
resolution, finding, or obligation is consulted upon with the Executive.

 

10.7 Expenses.
Expenses incurred by the Executive in connection with any Action (including the defense or settlement thereof) that may be subject
to a right of indemnification pursuant to this Section 10 shall be advanced to the Executive by the Company as such amounts are
incurred, or are reasonably expected to be incurred by the Executive.

 

10.8 Insurance.
Parent or the Company covenants to pay for, and maintain, adequate D&O insurance respecting any liabilities that may arise
pursuant to this Section 10 and provide proof of such insurance for (i) any Action arising after the date of this agreement and
(ii) any Prior Employer Action.

 

10.9 Survival.
The obligations contemplated in this Section 10 shall survive the expiration of the term, or termination, of the Executive’s
employment.

 

11. General
Provisions.

 

11.1 Notices.
Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery or the next
day after sending by overnight courier, to the Company at its primary office location and to the Executive at the Executive’s
address as listed on the Company payroll.

 

11.2 Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other
jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping
with the intent of the parties.

 

11.3 Waiver.
Any waiver of any party’s rights under this Agreement may be made only in a writing signed by such party. If either party
should waive any breach of any provisions of this Agreement, the party shall not thereby be deemed to have waived any preceding
or succeeding breach of the same or any other provision of this Agreement.

 

    13

     

    

 

11.4 Complete
Agreement. This Agreement and its Exhibits, Schedule A, and Appendix I, together with the restricted share
purchase agreements referenced on Appendix I constitute the entire agreement between the Executive and the Company and it
is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter. It is entered into without
reliance on any promise or representation other than those expressly contained herein or therein, as applicable.

 

11.5 Modification.
Changes in the Executive’s employment terms, other than those changes expressly reserved to the Company’s or Board’s
discretion in this Agreement, require a written modification approved by the Board or signed by a duly authorized Officer of the
Company, on the one hand, and the Executive, on the other hand.

 

11.6 Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but
all of which taken together will constitute one and the same Agreement, and pdf or other facsimile signatures shall be equivalent
to original signatures.

 

11.7 Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to
affect the meaning thereof.

 

11.8 Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by the Executive and the Company,
and their respective successors, assigns, heirs, executors and administrators, except that the Executive may not assign any of
Executive’s rights, obligations, or duties hereunder without the written consent of the Company, which shall not be withheld
unreasonably. The Company may assign its rights and obligations under this Agreement to any parent entity of the Company.

 

11.9 Survival.
The Executive’s duties under the Employee Confidential Information and Invention Assignment Agreement, and Sections 6,
7, 8, 9, and 10, shall survive termination of the Executive’s employment with the Company.

 

11.10 Remedies.
The Executive acknowledges that a remedy at law for any breach or threatened breach by the Executive of the provisions of this
Agreement, or the Employee Confidential Information and Invention Assignment Agreement, would be inadequate, and the Executive
therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach, in addition
to any other remedies available to the Company.

 

11.11 Attorneys’
Fees. If either party hereto brings any action to enforce Executive’s or its rights hereunder, each party shall be liable
for its own attorneys’ fees and costs incurred in connection with such action.

 

11.12 Choice
of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law
of the State of California, without giving effect to choice of law principles.

 

    14

     

    

 

In
Witness Whereof, the parties have executed this Agreement on the day and year first written above.

 

	 	CANOO INC. 
	 	 
	 	By:	/s/ Andrew Wolstan
	 	Andrew Wolstan
	 	In Charge of Legal & Government Affairs
	 	 
	 	Date:	November 25, 2020

 

Accepted and agreed this

25 day of November, 2020.

 

Ulrich Kranz

 

	/s/ Ulrich Kranz	 

 

 

15Exhibit 4.4

      

       

      

      WARRANT AGREEMENT

      

      

      THIS WARRANT AGREEMENT (this “Agreement”),
        dated as of [●], 2020, is by and between HumanCo Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer
        & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent,” also referred to herein as the “Transfer Agent”).

      

      

      WHEREAS, the Company is engaged in an initial public offering (the “Offering”) of units of the Company’s equity securities, each such unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (“Common Stock”), and one-half of one redeemable Public Warrant (as defined below) (the “Units”)
        and, in connection therewith, has determined to issue and deliver up to 11,250,000 warrants (or up to 12,937,500 warrants if the Over-allotment Option (as defined below) is exercised in full) to public investors in the Offering (the “Public Warrants”), each whole Public Warrant entitling the holder to purchase one share of Common Stock at an exercise price of $11.50 per
        share, subject to adjustment as described herein;

      

      

      WHEREAS, on [●], 2020, the Company entered into that certain Warrant Purchase Agreement with HumanCo Acquisition Holdings, LLC, a Delaware limited
        liability company (the “Sponsor”), pursuant to which the Sponsor agreed to purchase an aggregate of 6,825,000 warrants (or up to 7,500,000
        warrants if the Over-allotment Option is exercised in full) simultaneously with the closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing the legend set forth in Exhibit B hereto (the “Private Placement Warrants”), at a purchase price of $1.00 per Private Placement
        Warrant;

      

      

      WHEREAS, on [●], 2020, the Company entered into that certain Unit Purchase Agreement with CAVU Venture Partners III, LP, a Delaware limited
        partnership (“CAVU”), pursuant to which CAVU agreed to purchase 2,500,000 units (the “CAVU Units”) of the Company’s equity securities, each such unit comprised of one
        share of Common Stock (the “CAVU Shares”) and one-half of one redeemable warrant and, in connection therewith, has determined to issue and
        deliver 1,250,000 warrants to CAVU, bearing the legend set forth in Exhibit B hereto (the “CAVU Warrants”), each whole CAVU Warrant entitling the holder to purchase one share of Common Stock at an exercise price of $11.50 per share, subject to adjustment as described herein;

      

      

      WHEREAS, in order to finance the Company’s transaction costs in connection with an intended initial Business Combination (as defined below), the
        Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as the Company may require, of which up to $2,000,000 of such loans may be converted into warrants at a
        price of $1.00 per warrant at the option of the lender (the “Working Capital Warrants”);

      

      

      WHEREAS, following consummation of the Offering, the Company may issue additional warrants (“Post-IPO Warrants” and, together with the Private Placement Warrants, the CAVU Warrants, the Working Capital Warrants and the Public Warrants, the “Warrants”) in connection with, or following the consummation by the Company of, a Business Combination (defined below);

      

      

      WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, File No. 333-[●] (the “Registration Statement”),
        and a prospectus (the “Prospectus”), for the registration under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public Warrants and the Common Stock included in the Units;

      

      

      WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the
        issuance, registration, transfer, exchange, redemption and exercise of the Warrants;

      

      

      WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and
        the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

      

      

      WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and
        countersigned by or on behalf of the Warrant Agent (if a physical

       

      

      
        
          

      

      certificate is issued), as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.

      

      

      NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

      

      

      1. Appointment of Warrant Agent.

      

      

      The Company hereby appoints Continental Stock Transfer & Trust Company to act as agent for the Company for the Warrants, and Continental Stock
        Transfer & Trust Company hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

      

      

      2. Warrants.

      

      

      2.1 Form of Warrant. Each Warrant shall initially be issued in
        registered form only. Physical certificates, if issued, shall be signed by, or bear the facsimile signature of, the Chairman of the Board (as defined below), Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Secretary or
        other principal officer of the Company. In the event the person whose facsimile signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be
        issued with the same effect as if he or she had not ceased to be such at the date of issuance.

      

      

      2.2 Effect of Countersignature. If a physical certificate is issued,
        unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof.

      

      

      2.3 Registration.

      

      

      2.3.1 Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”) for the registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the
        Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. All of the Public
        Warrants shall initially be represented by one or more book-entry certificates (each, a “Book-Entry Warrant Certificate”) deposited with
        The Depository Trust Company (the “Depositary”) and registered in the name of Cede & Co., a nominee of the Depositary. Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through,
        records maintained by institutions that have accounts with the Depository (each such institution, with respect to a Warrant in its account, a “Participant”).

      

      

      If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the
        Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall
        provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to or upon the order of the Depositary definitive
        certificates in physical form evidencing such Warrants (“Definitive Warrant Certificates”) which shall be in the form annexed hereto as Exhibit A.

      

      

      2.3.2 Registered Holder. Prior to due presentment for registration of
        transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on any Definitive Warrant Certificate made by anyone other
        than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

      

      

      
        
          

      

      2.4 Detachability of Warrants. The Common Stock and the Public
        Warrants comprising the Units shall begin separate trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not a day, other than a Saturday, Sunday or federal holiday, on which banks in New York City are generally open
        for normal business (a “Business Day”), then on the immediately succeeding Business Day following such date, or earlier (the “Detachment Date”) with the consent of Citigroup Global Markets Inc., the underwriter of the Offering (the “Underwriter”), but in no event shall the Common Stock and the Public Warrants comprising the Units be separately traded until (A) the Company has filed (i) a Current
        Report on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds received by the Company from the exercise by the Underwriter of its right
        to purchase additional Units in the Offering (the “Over-allotment Option”), if the Over-allotment Option is exercised prior to the filing
        of the Current Report on Form 8-K, and (ii) a second or amended Current Report on Form 8-K to provide updated financial information to reflect the underwriter’s exercise of the Over-allotment Option, if the Over-allotment Option is exercised
        following the filing of the Current Report on Form 8-K pursuant to clause (i) above, and (B) the Company issues a press release and files with the Commission a Current Report on Form 8-K announcing when such separate trading shall begin.

       

      2.5 No Fractional Warrants Other Than as Part of Units. The Company
        shall not issue fractional Warrants other than as part of the Units. If, upon the detachment of Public Warrants from Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the
        nearest whole number the number of Warrants to be issued to such holder.

      

      

      2.6 Private Placement Warrants and Working Capital Warrants. The
        Private Placement Warrants, the CAVU Warrants and the Working Capital Warrants shall be identical to the Public Warrants, except that, solely with respect to the Private Placement Warrants and the Working Capital Warrants, so long as they are held
        by the original purchasers thereof or any Permitted Transferees (as defined below) they: (i) may be exercised for cash or on a cashless basis, pursuant to subsection 3.3.1(c)
        hereof and (ii) shall not be redeemable by the Company pursuant to Section 6.1 hereof. The Private Placement Warrants, the CAVU Warrants and the Working Capital Warrants
        including the shares of Common Stock issuable upon their exercise, subject to certain exceptions, may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of an initial Business Combination (as defined
        below); provided, however, that the Private Placement Warrants, the CAVU Warrants and the Working Capital Warrants and any shares of Common Stock issued upon exercise of the Private Placement Warrants, the CAVU Warrants or the Working Capital
        Warrants that, in each case, are held by the original purchasers thereof or any Permitted Transferees may be transferred by the holders thereof:

      

      

      (a) to the Company’s officers or directors, any affiliates or family members of any of the Company’s officers or directors, the Sponsor, any
        member(s) of the Sponsor, or any affiliates of the Sponsor or CAVU, or any affiliates of such members and funds and accounts advised by such members or any limited partners of any such funds that are invested in the Sponsor or the limited partners
        of CAVU;

      

      

      (b) in the case of an individual, by gift to a member of such individual’s immediate family or to a trust, the beneficiary of which is a member of
        such individual’s immediate family, an affiliate of such individual or to a charitable organization;

      

      

      (c) in the case of an individual, by virtue of the laws of descent and distribution upon death of such individual;

      

      

      (d) in the case of an individual, pursuant to a qualified domestic relations order;

      

      

      (e) by private sales or transfers made in connection with the consummation of the Company’s initial Business Combination at prices no greater than
        the price at which the Private Placement Warrants, the CAVU Warrants, the Working Capital Warrants or shares of Common Stock, as the case may be, were originally purchased;

      

      

      (f) to an entity that is an Affiliate of such holder;

      

      

      
        
          

      

      (g) in the event of the Company’s liquidation prior to the consummation of the Company’s initial Business Combination;

      

      

      (h) by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon liquidation or dissolution of the
        Sponsor;

      

      

      (i) in the event of the Company’s liquidation, merger, capital stock exchange, reorganization or other similar transaction which results in all of
        the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property subsequent to the Company’s completion of its initial Business Combination; or

      

      

      (j) to the Company for no value for cancellation in connection with the consummation of the Company’s initial Business Combination;

      

      

      provided, however,
        that, in the case of clauses (a) through (f) or (h), any such transferees (the “Permitted Transferees”) enter into a written agreement with
        the Company agreeing to be bound by the transfer restrictions in this Agreement. As used herein “Affiliate” means, with respect to any holder any other person who, directly or indirectly (including through one or more intermediaries), controls, is controlled by, or is under common control with,
        such person. For purposes of this definition, “control,” when used with respect to any specified person, shall mean the power, direct or indirect, to direct or cause the direction of the management and policies of such person, whether through
        ownership of voting securities or partnership or other ownership interests, by contract or otherwise; and the terms “controlling” and “controlled” shall have correlative meanings.

      

      

      2.7 Post-IPO Warrants. The Post-IPO Warrants, when and if issued,
        shall have the same terms and be in the same form as the Public Warrants, except as may be agreed upon by the Company.

      

      

      3. Terms and Exercise of Warrants.

      

      

      3.1 Warrant Price. Each whole Warrant shall entitle the Registered
        Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. The term “Warrant Price” as used
        in this Agreement shall mean the price per share (including in cash or by payment of Warrants pursuant to a “cashless exercise,” to the extent permitted hereunder) at which shares of Common Stock may be purchased at the time a Warrant is exercised.
        The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days (unless otherwise required by the Commission, any national securities
        exchange on which the Warrants are listed or applicable law); provided, that the Company shall provide at least three (3) Business Days prior written notice of such reduction to Registered Holders of the Warrants and, provided further that any such
        reduction shall be identical among all of the Warrants.

       

      3.2 Duration of Warrants. A Warrant may be exercised only during the
        period (the “Exercise Period”) commencing on the later of: (i) the date that is thirty (30) days after the first date on which the Company
        completes a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses (a “Business Combination”), and (ii) the date that is twelve (12) months from the date of the closing of the Offering, and terminating at 5:00 p.m., New York City time, on the earlier to occur of: (x)
        the date that is five (5) years after the date on which the Company completes its initial Business Combination, (y) the commencement of the winding up and liquidation of the Company in accordance with the Company’s amended and restated certificate
        of incorporation, as amended from time to time, if the Company fails to complete a Business Combination, or (z) other than with respect to the Private Placement Warrants and the Working Capital Warrants to the extent then held by the original
        purchasers thereof or their Permitted Transferees, the Redemption Date (as defined below) as provided in Section 6.3 hereof (the “Expiration Date”); provided, however, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in subsection 3.3.2 below
        with respect to an effective registration statement or a valid exemption therefrom being available. Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect to a Private Placement Warrant or a
        Working Capital Warrant to the extent then held by the original purchasers thereof or their Permitted Transferees in the event of a redemption (as set forth in Section

       

          

      
        
          

      

      6 hereof)), each outstanding Warrant (other than a Private Placement Warrant or a Working
        Capital Warrant to the extent then held by the original purchasers thereof or their Permitted Transferees in the event of a redemption) not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in
        respect thereof under this Agreement shall cease at 5:00 p.m., New York City time, on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall
        be identical in duration among all the Warrants.

      

      

      3.3 Exercise of Warrants.

      

      

      3.3.1 Payment. Subject to the provisions of the Warrant and this
        Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a
        Book-Entry Warrant Certificate, the Warrants to be exercised (the “Book-Entry Warrants”) on the records of the Depositary, to an account of
        the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (“Election to Purchase”) any shares of Common Stock pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case of
        a Book-Entry Warrant, properly delivered by the Participant in accordance with the Depositary’s procedures, and (iii) the payment in full of the Warrant Price for each full share of Common Stock as to which the Warrant is exercised and any and all
        applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the shares of Common Stock and the issuance of such shares of Common Stock, as follows:

      

      

      (a) in lawful money of the United States, by certified check payable to the order of the Warrant Agent or by wire transfer;

      

      

      (b) [Reserved];

      

      

      (c) with respect to any Private Placement Warrant or Working Capital Warrant, so long as such Private Placement Warrant or Working Capital Warrant
        is held by the original purchasers thereof or their Permitted Transferees, as applicable, by surrendering the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of
        Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value”, as defined in this subsection 3.3.1(c), over the Warrant Price by (y) the Fair
        Market Value. Solely for purposes of this subsection 3.3.1(c), the “Fair Market Value” shall mean the average of the last reported sale prices of the Common Stock for the
        ten (10) trading days ending on the third trading day prior to the date on which notice of exercise of the Warrant is received by the Warrant Agent;

       

      (d) as provided in Section 6.2 hereof with respect to a Make-Whole
        Exercise;

       

      (e) as provided in Section 7.4 hereof.

      

      

      3.3.2 Issuance of Shares of Common Stock upon Exercise. As soon as
        practicable after the exercise of any Warrant and the clearance of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company
        shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number of full shares of Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him,
        her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of shares of Common Stock as to which such Warrant shall not have been exercised.
        Notwithstanding the foregoing and subject to the Company satisfying its obligations in Section 7.4, the Company shall not be obligated to deliver any shares of Common Stock pursuant to the exercise of a Warrant and shall have no obligation to
        settle such Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the Warrants is then effective and a prospectus relating thereto is current, or a valid exemption from
        registration is available. No Warrant shall be exercisable and the Company shall not be obligated to issue shares of Common Stock upon exercise of a Warrant unless the Common Stock issuable upon such Warrant exercise has been registered, qualified
        or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the Registered Holder of the Warrants. In the event that the conditions in the two immediately preceding sentences are

       

      

      
        
          

      

      not satisfied with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant and such Warrant may have no value and expire
        worthless, in which case the purchaser of a Unit containing such Public Warrants shall have paid the full purchase price for the Unit solely for the shares of Common Stock underlying such Unit. In no event will the Company be required to net cash
        settle the exercise of any Warrant. The Company may require holders of Public Warrants and CAVU Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4
        hereof. If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the Company shall round down to
        the nearest whole number, the number of shares of Common Stock to be issued to such holder.

      

      

      3.3.3 Valid Issuance. All shares of Common Stock issued upon the
        proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and non-assessable.

      

      

      3.3.4 Date of Issuance. Each person in whose name any book-entry
        position or certificate, as applicable, for shares of Common Stock is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which the Warrant, or book-entry position representing
        such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the share
        transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the share
        transfer books or book-entry system are open.

      

      

      3.3.5 Maximum Percentage. A holder of a Warrant may notify the
        Company in writing in the event he, she or it elects to be subject to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such election. If the election is
        made by a holder, the Warrant Agent shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such holder (together with such
        holder’s affiliates or any other person subject to aggregation with such person for purposes of the “beneficial ownership” test under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any “group” (within the meaning of Section 13 of the Exchange Act) of which such person is or may be deemed to be a part), to the Warrant Agent’s actual
        knowledge, would beneficially own (within the meaning of Section 13 of the Exchange Act) (or to the extent that for any reason the equivalent calculation under Section 16 of the Exchange Act and the rules and regulations thereunder would result in
        a higher ownership percentage, such higher percentage would be) in excess of 4.9% or 9.8% (or such other amount as a holder may specify) (the “Maximum
          Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such holder and his, her
        or its affiliates or any such other person or group shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common
        Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such holder and his, her or its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any
        other securities of the Company beneficially owned by such holder and his, her or its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise
        analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes of the Warrant,
        in determining the number of outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q,
        Current Report on Form 8-K or other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common
        Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of shares of Common Stock then
        outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and his, her or its affiliates since the date as of
        which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage
        specified in such notice; provided,

       

      

      
        
          

      

      however, that any such increase shall not be effective until the sixty-first (61st) day
        after such notice is delivered to the Company.

       

      4. Adjustments.

      

      

      4.1 Stock Dividends.

      

      

      4.1.1 Split-Ups. If after the date hereof, and subject to the
        provisions of Section 4.6 below, the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of
        shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be increased in proportion to such
        increase in the outstanding shares of Common Stock. A rights offering to holders of the Common Stock entitling holders to purchase shares of Common Stock at a price less than the “Fair Market Value” (as defined below) shall be deemed a stock
        dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible
        into or exercisable for the Common Stock) and (ii) one (1) minus the quotient of (x) the price per share of Common Stock paid in such rights offering divided by (y) the Fair Market Value. For purposes of this subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in determining the price payable for Common Stock, there shall be taken into account
        any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) “Fair Market Value” means the volume weighted average price of the Common Stock as reported during the ten (10) trading day
        period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.

      

      

      4.1.2 Extraordinary Dividends. If the Company, at any time while the
        Warrants are outstanding and unexpired, shall pay a dividend or make a distribution in cash, securities or other assets to the holders of the Common Stock on account of such shares of Common Stock (or other shares of the Company’s capital stock
        into which the Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the
        redemption rights of the holders of the Common Stock in connection with a proposed initial Business Combination by the Company, (d) to satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend the
        Company’s amended and restated certificate of incorporation to (i) modify the substance or timing of the Company’s obligation to allow redemption in connection with its initial Business Combination or the Company’s obligation to redeem 100% of the
        shares of Common Stock included in the Units sold in the Offering and the CAVU Shares if the Company does not complete its initial Business Combination within the time period set forth in the Company’s amended and restated certificate of
        incorporation or (ii) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity or (e) in connection with the redemption of the shares of Common Stock included in the Units sold in the
        Offering and the CAVU Shares upon the failure of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary
        Dividend, by the amount of cash and/or the fair market value (as determined by the Company’s Board of Directors (the “Board”), in good
        faith) of any securities or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis, with the per share amounts of
        all other cash dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other
        subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares of Common
        Stock issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units in the Offering). Solely for purposes of illustration, if the Company, at a time while the Warrants are outstanding and unexpired, pays a
        cash dividend of $0.35 per share and previously paid an aggregate of $0.40 of cash dividends and cash distributions on the shares of Common Stock during the 365-day period ending on the date of declaration of such $0.35 per share dividend, then the
        Warrant Price will be decreased, effective immediately after the effective date of such $0.35 per share dividend, by $0.25 (the absolute value of the difference between $0.75 per share (the aggregate amount of all cash dividends and cash
        distributions paid or made in such 365-day

       

      

      
        
          

      

      period, including such $0.35 dividend) and $0.50 per share (the greater of (x) $0.50 per share and (y) the aggregate amount of all cash dividends and cash
        distributions paid or made in such 365-day period prior to such $0.35 dividend)).

       

      4.2 Aggregation of Shares. If after the date hereof, and subject to
        the provisions of Section 4.6 hereof, the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or
        reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of
        each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock.

      

      

      4.3 Adjustments in Warrant Price.

      

      

      4.3.1 Whenever the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent)
        by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and
        (y) the denominator of which shall be the number of shares of Common Stock so purchasable immediately thereafter.

      

      

      4.3.2 If (x) the Company issues additional shares of Common Stock or securities convertible into or exercisable or exchangeable for shares of
        Common Stock for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Common Stock (with such issue price or effective issue price to
        be determined in good faith by the Board and, (i) in the case of any such issuance to HumanCo LLC (“HumanCo”), CAVU, the Sponsor or any of
        their respective affiliates, without taking into account any shares of Class B common stock of the Company, par value $0.0001 per share (the “Class
          B Common Stock”), or CAVU Shares held by HumanCo, CAVU, the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii) to the extent that such issuance is made to HumanCo, CAVU or any of their respective affiliates,
        without taking into account the transfer of Class B Common Stock, CAVU Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor, HumanCo
        or CAVU  in connection with such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more
        than 60% of the total equity proceeds, and interest thereon, available for the funding of an initial Business Combination on the date of the consummation of such initial Business Combination (net of redemptions), and (z) the volume weighted average
        trading price of the Common Stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates an initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the Warrant Price will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00
        per share redemption trigger price described in Section 6.1 and Section 6.2 shall be
        adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described in Section 6.2 shall be adjusted (to the nearest cent) to be equal to the
        higher of the Market Value and the Newly Issued Price.

       

      4.4 Replacement of Securities upon Reorganization, etc. In case of any
        reclassification or reorganization of the outstanding shares of Common Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value of such shares of Common Stock), or in the case of any merger or
        consolidation of the Company with or into another entity or conversion of the Company as another entity (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or
        reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with
        which the Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company
        immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
        merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the “Alternative Issuance”);

       

      

      
        
          

      

      provided, however,
        that (i) if the holders of the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or
        other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by the holders of the Common Stock in such consolidation or
        merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange or redemption offer made by the Company in
        connection with redemption rights held by stockholders of the Company as provided for in the Company’s amended and restated certificate of incorporation or as a result of the repurchase of shares of Common Stock by the Company if a proposed initial
        Business Combination is presented to the stockholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule
        13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members
        of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than 50% of the outstanding shares of Common Stock, the holder of a
        Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such Warrant holder had exercised the Warrant
        prior to the expiration of such tender or exchange offer, accepted such offer and all of the Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of
        such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4; provided, further, that if less than 70% of the consideration receivable by the holders of the Common Stock in the applicable event is payable in
        the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and
        if the Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the
        Warrant Price shall be reduced by an amount (in dollars) (but in no event less than zero) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the
        Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the
        consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (“Bloomberg”).
        For purposes of calculating such amount, (1) Section 6 of this Agreement shall be taken into account, (2) the price of each share of Common Stock shall be the volume
        weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day volatility obtained from the
        HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period equal to the
        remaining term of the Warrant. “Per Share Consideration” means (i) if the consideration paid to holders of the Common Stock consists
        exclusively of cash, the amount of such cash per share of Common Stock, and (ii) in all other cases, the amount of cash per share of Common Stock, if any, paid to holders plus the volume weighted average price of the Common Stock as reported during
        the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event. If any reclassification or reorganization also results in a change in shares of Common Stock covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3 and this Section 4.4.
        The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no
        event will the Warrant Price be reduced to less than the par value per share issuable upon exercise of the Warrant.

       

      4.5 Notices of Changes in Warrant. Upon every adjustment of the
        Warrant Price or the number of shares of Common Stock issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the
        increase or decrease, if any, in the number of shares of Common Stock purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon
        the occurrence of any event specified in Sections 4.1, 4.2, 4.3 or 4.4, the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the
        last address set forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

      

      

      
        
          

      

      4.6 No Fractional Shares. Notwithstanding any provision contained in
        this Agreement to the contrary, the Company shall not issue fractional shares of Common Stock upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this Section
            4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of shares of
        Common Stock to be issued to such holder.

      

      

      4.7 Form of Warrant. The form of Warrant need not be changed because
        of any adjustment pursuant to this Section 4, and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares of Common Stock as
        is stated in the Warrants initially issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect
        the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

      

      

      4.8 Other Events. In case any event shall occur affecting the Company
        as to which none of the provisions of the preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the
        Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall
        appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to
        effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment; provided, however, that under no circumstances shall the Warrants be adjusted pursuant to this Section 4.8 as a result of any issuance of securities in connection with a Business Combination. The Company shall adjust the terms of the Warrants in a manner that is consistent with any
        adjustment recommended in such opinion.

      

      

      4.9 No Adjustment. For the avoidance of doubt, no adjustment shall be
        made to the terms of the Warrants solely as a result of an adjustment to the conversion ratio of the Class B Common Stock into shares of Common Stock or the conversion of the shares of Class B Common Stock into shares of Common Stock, in each case,
        pursuant to the Company’s amended and restated certificate of incorporation, as may be amended from time to time.

      

      

      5. Transfer and Exchange of Warrants.

      

      

      5.1 Registration of Transfer. The Warrant Agent shall register the
        transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of certificated Warrants, properly endorsed with signatures properly guaranteed and accompanied by
        appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the
        Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.

      

      

      5.2 Procedure for Surrender of Warrants. Warrants may be surrendered
        to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered,
        representing an equal aggregate number of Warrants; provided, however, that except as otherwise provided herein or in any Book-Entry Warrant Certificate, each Book-Entry Warrant Certificate may be transferred only in whole and only to the
        Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of
        the Private Placement Warrants, the CAVU Warrants and the Working Capital Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received an opinion of counsel for the
        Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

      

      

      
        
          

      

      5.3 Fractional Warrants. The Warrant Agent shall not be required to
        effect any registration of transfer or exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.

      

      

      5.4 Service Charges. No service charge shall be made for any exchange
        or registration of transfer of Warrants.

      

      

      5.5 Warrant Execution and Countersignature. The Warrant Agent is
        hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5,
        and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

      

      

      5.6 Transfer of Warrants. Prior to the Detachment Date, the Public
        Warrants may be transferred or exchanged only together with the Unit in which such Public Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore, each transfer of a Unit
        on the register relating to such Unit shall operate also to transfer the Public Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6
        shall have no effect on any transfer of Warrants on and after the Detachment Date.

      

      

      6. Redemption.

      

      

      6.1 Redemption of Warrants for Cash at $0.01 Per Warrant. Subject to Section 6.5 hereof, at any time during the Exercise Period, the Company may, at its option, redeem all (and not part) of the outstanding Warrants at the office of the Warrant
        Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price (as defined in Section 6.3 hereof) of $0.01 per
        Warrant, provided that (a) the last reported sale price of the Common Stock for any 10 trading days within a 20-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the
        Registered Holders equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof) and (b) there is an effective registration statement covering the shares of Common Stock issuable upon exercise of the Warrants, and a
        current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.3 below).

      

      

      6.2 Redemption of Warrants for Cash at $0.10 Per Warrant. Subject to Section 6.5 hereof, at any time during the Exercise Period, the Company may, at its option, redeem all (and not part) of the outstanding Warrants at the office of the Warrant
        Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price of $0.10 per Warrant, provided that the last
        reported sale price of the Common Stock for any 10 trading days within a 20-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Registered Holder equals or exceeds $10.00
        per share (subject to adjustment in compliance with Section 4 hereof) and, if the last reported sale price of the Common Stock for any 10 trading days within a 20-trading
        day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Registered Holder is less than $18.00 per share (subject to adjustment in compliance with Section 4 hereof), the Private Placement Warrants are also concurrently called for redemption on the same terms as the outstanding Public Warrants. During the 30-day Redemption Period in connection
        with a redemption pursuant to this Section 6.2, Registered Holders of the Warrants may elect to exercise their Warrants on a “cashless basis” and receive a number of
        shares of Common Stock determined by reference to the table below, based on the Redemption Date (calculated for purposes of the table as the period to expiration of the Warrants) and the “Redemption Fair Market Value” (as such term is defined in
        this Section 6.2) (a “Make-Whole Exercise”). Solely for
        purposes of this Section 6.2, the “Redemption Fair Market Value” shall mean the volume-weighted average price of the Common Stock as reported during the ten (10) trading days immediately
        following the date on which notice of redemption pursuant to this Section 6.2 is sent to the Registered Holders. In connection with any redemption pursuant to this Section 6.2, the Company shall provide the Registered Holders with the Redemption Fair Market Value no later than one (1) Business Day after the ten (10) trading day period
        described above ends.

      

      

      
        
          

      

      	
              Redemption Date

            	
              
                Redemption Date Fair Market Value of Common Stock

              

            
	 	 
	
              (period to expiration of warrants)

            	
              
                <10.00

              

            	
              
                11.00

              

            	
              
                12.00

              

            	
              
                13.00

              

            	
              
                14.00

              

            	
              
                15.00

              

            	
              
                16.00

              

            	
              
                17.00

              

            	
              
                >18.00

              

            
	
              60 months

            	
              0.261

            	
              0.281

            	
              0.297

            	
              0.311

            	
              0.324

            	
              0.337

            	
              0.348

            	
              0.358

            	
              0.361

            
	
              57 months

            	
              0.257

            	
              0.277

            	
              0.294

            	
              0.310

            	
              0.324

            	
              0.337

            	
              0.348

            	
              0.358

            	
              0.361

            
	
              54 months

            	
              0.252

            	
              0.272

            	
              0.291

            	
              0.307

            	
              0.322

            	
              0.335

            	
              0.347

            	
              0.357

            	
              0.361

            
	
              51 months

            	
              0.246

            	
              0.268

            	
              0.287

            	
              0.304

            	
              0.320

            	
              0.333

            	
              0.346

            	
              0.357

            	
              0.361

            
	
              48 months

            	
              0.241

            	
              0.263

            	
              0.283

            	
              0.301

            	
              0.317

            	
              0.332

            	
              0.344

            	
              0.356

            	
              0.361

            
	
              45 months

            	
              0.235

            	
              0.258

            	
              0.279

            	
              0.298

            	
              0.315

            	
              0.330

            	
              0.343

            	
              0.356

            	
              0.361

            
	
              42 months

            	
              0.228

            	
              0.252

            	
              0.274

            	
              0.294

            	
              0.312

            	
              0.328

            	
              0.342

            	
              0.355

            	
              0.361

            
	
              39 months

            	
              0.221

            	
              0.246

            	
              0.269

            	
              0.290

            	
              0.309

            	
              0.325

            	
              0.340

            	
              0.354

            	
              0.361

            
	
              36 months

            	
              0.213

            	
              0.239

            	
              0.263

            	
              0.285

            	
              0.305

            	
              0.323

            	
              0.339

            	
              0.353

            	
              0.361

            
	
              33 months

            	
              0.205

            	
              0.232

            	
              0.257

            	
              0.280

            	
              0.301

            	
              0.320

            	
              0.337

            	
              0.352

            	
              0.361

            
	
              30 months

            	
              0.196

            	
              0.224

            	
              0.250

            	
              0.274

            	
              0.297

            	
              0.316

            	
              0.335

            	
              0.351

            	
              0.361

            
	
              27 months

            	
              0.185

            	
              0.214

            	
              0.242

            	
              0.268

            	
              0.291

            	
              0.313

            	
              0.332

            	
              0.350

            	
              0.361

            
	
              24 months

            	
              0.173

            	
              0.204

            	
              0.233

            	
              0.260

            	
              0.285

            	
              0.308

            	
              0.329

            	
              0.348

            	
              0.361

            
	
              21 months

            	
              0.161

            	
              0.193

            	
              0.223

            	
              0.252

            	
              0.279

            	
              0.304

            	
              0.326

            	
              0.347

            	
              0.361

            
	
              18 months

            	
              0.146

            	
              0.179

            	
              0.211

            	
              0.242

            	
              0.271

            	
              0.298

            	
              0.322

            	
              0.345

            	
              0.361

            
	
              15 months

            	
              0.130

            	
              0.164

            	
              0.197

            	
              0.230

            	
              0.262

            	
              0.291

            	
              0.317

            	
              0.342

            	
              0.361

            
	
              12 months

            	
              0.111

            	
              0.146

            	
              0.181

            	
              0.216

            	
              0.250

            	
              0.282

            	
              0.312

            	
              0.339

            	
              0.361

            
	
              9 months

            	
              0.090

            	
              0.125

            	
              0.162

            	
              0.199

            	
              0.237

            	
              0.272

            	
              0.305

            	
              0.336

            	
              0.361

            
	
              6 months

            	
              0.065

            	
              0.099

            	
              0.137

            	
              0.178

            	
              0.219

            	
              0.259

            	
              0.296

            	
              0.331

            	
              0.361

            
	
              3 months

            	
              0.034

            	
              0.065

            	
              0.104

            	
              0.150

            	
              0.197

            	
              0.243

            	
              0.286

            	
              0.326

            	
              0.361

            
	
              0 months

            	
              —

            	
              —

            	
              0.042

            	
              0.115

            	
              0.179

            	
              0.233

            	
              0.281

            	
              0.323

            	
              0.361

            

      

      

      The exact Redemption Fair Market Value and Redemption Date (as defined below) may not be set forth in the table above, in which case, if the
        Redemption Fair Market Value is between two values in the table or the Redemption Date is between two redemption dates in the table, the number of shares of Common Stock to be issued for each Warrant exercised in a Make-Whole Exercise will be
        determined by a straight-line interpolation between the number of shares set forth for the higher and lower Redemption Fair Market Values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.

      

      

      The share prices set forth in the column headings of the table above shall be adjusted as of any date on which the number of shares of Common Stock
        issuable upon exercise of a Warrant or the Warrant Price is adjusted pursuant to Section 4 hereof. If the number of shares of Common Stock issuable upon exercise of a
        Warrant is adjusted pursuant to Section 4 hereof, the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the Warrant Price after such
        adjustment and the denominator of which is the Warrant Price immediately prior to such adjustment. In such an event, the number of shares in the table above shall be adjusted by multiplying such share amounts by a fraction, the numerator of which
        is the number of shares deliverable upon exercise of a Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. If the Warrant Price is adjusted, (a) in
        the case of an adjustment pursuant to Section 4.3.2 hereof, the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment multiplied by a fraction, the numerator of which is the higher of the
        Market Value and the Newly Issued Price and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to Section 4.1.2 hereof, the adjusted share
        prices in the column headings shall equal the share prices immediately prior to such adjustment less the decrease in the Warrant Price pursuant to such Warrant Price adjustment. In no event shall the number of shares issued in connection with a
        Make-Whole Exercise exceed 0.361 shares of Common Stock per Warrant (subject to adjustment).

      

      

      6.3 Date Fixed for, and Notice of, Redemption. In the event that the
        Company elects to redeem all of the Warrants, pursuant to Sections 6.1 or 6.2, the Company
        shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by first class mail, postage prepaid, by
        the Company not less than

      

      

      
        
          

      

      thirty (30) days prior to the Redemption Date (the “30-day
          Redemption Period”) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have
        been duly given whether or not the Registered Holder received such notice. As used in this Agreement, “Redemption Price” shall mean the
        price per Warrant at which any Warrants are redeemed pursuant to Section 6.1 or Section 6.2
        hereof.

      

      

      6.4 Exercise After Notice of Redemption. The Warrants may be exercised
        for cash (or, at the Registered Holder’s election, on a “cashless basis” in accordance with Section 6.2 hereof) at any time after notice of redemption pursuant to Section 6.1 or 6.2 hereof, as applicable, shall have been given by the Company pursuant to Section 6.3 hereof and prior to the Redemption Date. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon
        surrender of the Warrants, the Redemption Price.

      

      

      6.5 Exclusion of Private Placement Warrants and Working Capital Warrants.
        The Company agrees that the redemption rights provided in Section 6.1 hereof shall not apply to the Private Placement Warrants or the Working Capital Warrants if at the
        time of the redemption such Private Placement Warrants or Working Capital Warrants continue to be held by the original purchasers thereof or their Permitted Transferees. However, once such Private Placement Warrants or Working Capital Warrants are
        transferred (other than to Permitted Transferees in accordance with Section 2.6 hereof), the Company may redeem the Private Placement Warrants or Working Capital Warrants
        pursuant to Section 6.1 hereof, provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants or Working
        Capital Warrants to exercise such Private Placement Warrants or Working Capital Warrants prior to redemption pursuant to Section 6.4 hereof. Private Placement Warrants or
        Working Capital Warrants that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be Private Placement Warrants or Working Capital Warrants and shall become Public Warrants under this Agreement.

       

      7. Other Provisions Relating to Rights of Holders of Warrants.

      

      

      7.1 No Rights as Stockholder. A Warrant does not entitle the
        Registered Holder thereof to any of the rights of a stockholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as a
        stockholder in respect of the meetings of stockholders or the election of directors of the Company or any other matter.

      

      

      7.2 Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is
        lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a
        new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen,
        mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

      

      

      7.3 Reservation of Common Stock. The Company shall at all times
        reserve and keep available a number of its authorized but unissued shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

      

      

      7.4 Registration of Common Stock; Cashless Exercise at Company’s Option.

      

      

      7.4.1 Registration of the Common Stock. The Company agrees that as
        soon as practicable, but in no event later than fifteen (15) Business Days after the closing of its initial Business Combination, it shall use its commercially reasonable efforts to file with the Commission a registration statement for the
        registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants. The Company shall use its commercially reasonable efforts to cause the same to become effective within 60 Business Days after the closing
        of the Company’s initial Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of this
        Agreement. If any such registration statement has not been declared effective by the 60th Business Day following the closing of the Company’s initial Business Combination, holders of the Warrants shall have the right, during the period beginning on
        the 61st Business Day after the closing of the Business Combination and ending upon such registration statement being declared effective by the

       

      

      
        
          

      

      Commission, and during any other period when the Company shall fail to have maintained an effective registration statement covering the shares of Common Stock issuable
        upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of shares of Common
        Stock equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) over the Warrant Price by (y)
        the Fair Market Value and (B) 0.361 per whole Warrant. Solely for purposes of this subsection 7.4.1, “Fair Market Value” shall mean the average of reported last sale
        price of the Common Stock as reported during the ten (10) trading day period ending on the third trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or his, her or its securities
        broker or intermediary. The date that notice of cashless exercise is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Public Warrant, the Company shall, upon
        request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a cashless basis in accordance with this subsection 7.4.1 is not required to be registered under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be freely tradable under United
        States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as
        provided in subsection 7.4.2, for the avoidance of any doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be
        obligated to comply with its registration obligations under the first three sentences of this subsection 7.4.1.

      

      

      7.4.2  Cashless Exercise at Company’s Option. If the Common Stock is at
        the time of any exercise of a Public Warrant or a CAVU Warrant not listed on a national securities exchange such that, as a result, the Common Stock does not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities
        Act (or any successor statute), the Company may, at its option, (i) require holders of Public Warrants or CAVU Warrants who exercise Public Warrants or CAVU Warrants to exercise such Public Warrants or CAVU Warrants on a “cashless basis” in
        accordance with Section 3(a)(9) of the Securities Act (or any successor statute) as described in subsection 7.4.1 and (ii) in the event the Company so elects, the Company shall not be required to file or maintain in effect a registration statement
        for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify
        for sale the shares of Common Stock issuable upon exercise of the Public Warrant or CAVU Warrant under applicable blue sky laws to the extent an exemption is not available.

      

      

      8. Concerning the Warrant Agent and Other Matters.

      

      

      8.1 Payment of Taxes. The Company shall from time to time promptly pay
        all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in
        respect of the Warrants or such shares of Common Stock.

      

      

      8.2 Resignation, Consolidation, or Merger of Warrant Agent.

      

      

      8.2.1 Appointment of Successor Warrant Agent. The Warrant Agent, or
        any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant Agent becomes vacant by
        resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been
        notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the
        Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation or
        other entity organized and existing under the laws of the State of New York, in good standing and having its principal office in the United States of America, and authorized under such laws to exercise corporate trust powers and subject to
        supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect
        as if originally named as

       

      

      
        
          

      

      Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and
        deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall
        make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

      

      

      8.2.2 Notice of Successor Warrant Agent. In the event a successor
        Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any such appointment.

      

      

      8.2.3 Merger or Consolidation of Warrant Agent. Any entity into which
        the Warrant Agent may be merged or with which it may be consolidated or any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further
        act.

      

      

      8.3 Fees and Expenses of Warrant Agent.

      

      

      8.3.1 Remuneration. The Company agrees to pay the Warrant Agent
        reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the
        execution of its duties hereunder.

       

      8.3.2 Further Assurances. The Company agrees to perform, execute,
        acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the
        provisions of this Agreement.

      

      

      8.4 Liability of Warrant Agent.

      

      

      8.4.1 Reliance on Company Statement. Whenever in the performance of
        its duties under this Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in
        respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, President, Secretary or Chairman of the Board of the Company
        and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

      

      

      8.4.2 Indemnity. The Warrant Agent shall be liable hereunder only for
        its own gross negligence, willful misconduct, fraud or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, out-of-pocket costs and reasonable outside counsel fees,
        for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct, fraud or bad faith.

      

      

      8.4.3 Exclusions. The Warrant Agent shall have no responsibility with
        respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition
        contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible to make any adjustments required under the provisions of Section 4 hereof or
        responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the
        authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common Stock shall, when issued, be valid and fully paid and non-assessable.

      

      

      8.5 Acceptance of Agency. The Warrant Agent hereby accepts the agency
        established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things,

       

      

      
        
          

      

      shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent
        for the purchase of shares of Common Stock through the exercise of the Warrants.

      

      

      8.6 Waiver. The Warrant Agent has no right of set-off or any other
        right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account (as defined in that certain
        Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the
        Trust Account for any reason whatsoever. The Warrant Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

      

      

      9. Miscellaneous Provisions.

      

      

      9.1 Successors. All the covenants and provisions of this Agreement by
        or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

      

      

      9.2 Notices. Any notice, statement or demand authorized by this
        Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within
        five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:

      

      

      HumanCo Acquisition Corp.

      P.O. Box 90608

      Austin, TX 78709

      Attn: Amy Zipper

      Email: amy@humanco.com

      

      

      Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be
        sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing
        by the Warrant Agent with the Company), as follows:

       

      

      Continental Stock Transfer & Trust Company

      1 State Street, 30th Floor

      New York, NY 10004

      Attn: Compliance Department

      

      

      With a copy in each case to:

      

      

      Ropes & Gray LLP

      1211 Avenue of the Americas

      New York, NY 10036

      Attention: Paul Tropp

      Email: paul.tropp@ropesgray.com

      

      

      and

      

      

      Citigroup Global Markets Inc.

      388 Greenwich Street

      New York, New York 10013

      Attn: [●]

      Email: [●]

      

      

      and

      

      

      
        
          

      

      Davis Polk & Wardwell LLP

      450 Lexington Avenue

      New York, NY 10016

      Attn: Derek Dostal

      Email: derek.dostal@davispolk.com

      

      

      9.3 Applicable Law and Exclusive Forum. The validity, interpretation, and
        performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another
        jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court
        for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim.. The Company hereby waives any objection to such jurisdiction and that
        such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal
        district courts of the United States of America are the sole and exclusive forum.

      

      

      Any person or entity purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the
        forum provisions in this Section 9.3. If any action, the subject matter of which is within the scope of the forum provisions above, is filed in a court other than a court located within the State of New York or the United States District Court for
        the Southern District of New York (a “foreign action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of New York
        or the United States District Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y) having service of process made upon such warrant
        holder in any such enforcement action by service upon such warrant holder’s counsel in the foreign action as agent for such warrant holder.

      

      

      9.4 Persons Having Rights under this Agreement. Nothing in this
        Agreement shall be construed to confer upon, or give to, any person, corporation or other entity other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any
        covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and
        assigns and of the Registered Holders of the Warrants.

      

      

      9.5 Examination of the Warrant Agreement. A copy of this Agreement
        shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit
        such holder’s Warrant for inspection by the Warrant Agent.

      

      

      9.6 Counterparts. This Agreement may be executed in any number of
        original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. A signed copy of this Agreement delivered by
        facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

      

      

      9.7 Effect of Headings. The section headings herein are for
        convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

      

      

      9.8 Amendments. This Agreement may be amended by the parties hereto
        without the consent of any Registered Holder (i) for the purpose of curing any ambiguity or to correct any mistake, including to conform the provisions hereof to the description of the terms of the Warrants and this Agreement set forth in the
        Prospectus, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable
        and that the parties deem shall not adversely affect the interest of the Registered Holders, and (ii) to

      
        
          

      

      provide for the delivery of Alternative Issuance pursuant to Section 4.4. All other
        modifications or amendments, including any amendment to increase the Warrant Price or shorten the Exercise Period, shall require the vote or written consent of the Registered Holders of at least 50% of the then outstanding Public Warrants and,
        solely with respect to any amendment to the terms of the Private Placement Warrants, CAVU Warrants or Working Capital Warrants or any provision of this Agreement with respect to the Private Placement Warrants, CAVU Warrants or Working Capital
        Warrants, at least 50% of the number of then outstanding Private Placement Warrants, CAVU Warrants and Working Capital Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period
        pursuant to Sections 3.1 and 3.2, respectively, without the consent of the Registered
        Holders.

      

      

      9.9 Severability. This Agreement shall be deemed severable, and the
        invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision,
        the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

      

      

      Exhibit A – Form of Warrant Certificate

      Exhibit B – Legend

      

      

      [Signature Page Follows]

       

      

      
        
          

      

      	 	
              HUMANCO ACQUISITION CORP.

            
	 	 	 
	 	
              By:

            	 
	 	
              Name:

            	 
	 	
              Title:

            	 
	 	 	 
	 	
              CONTINENTAL STOCK TRANSFER & TRUST 

              COMPANY, as Warrant Agent

            
	 	 	 
	 	
              By:

            	 
	 	
              Name:

            	 
	 	
              Title:

            	 

      

      

      [Signature Page to Warrant Agreement]

      
        
          

      

      EXHIBIT A

      

      

      [Form of Warrant Certificate]

      

      

      [FACE]

      Number

      WARRANTS

      

      

      THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO

      THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

      IN THE WARRANT AGREEMENT DESCRIBED BELOW

      

      

      HUMANCO ACQUISITION CORP.

      Incorporated Under the Laws of the State of Delaware

      CUSIP [__________]

      Warrant Certificate

      

      

      This Warrant Certificate certifies that
        __________, or its registered assigns, is the registered holder of __________ warrant(s) evidenced hereby (the “Warrants” and each, a “Warrant”) to purchase shares of Class A common stock, $0.0001 par value per share (“Common Stock”), of HumanCo Acquisition Corp., a Delaware corporation (the “Company”).
        Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and non-assessable shares of Common Stock as set forth below, at the
        exercise price (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and
        payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have
        the meanings given to them in the Warrant Agreement.

      

      

      Each whole Warrant is initially exercisable for one fully paid and non-assessable share of Common Stock. No fractional shares will be issued upon
        exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share of Common Stock, the Company will, upon exercise, round down to the nearest whole number the number of shares of
        Common Stock to be issued to the Warrant holder. The number of shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

      

      

      The initial Exercise Price per share of Common Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon
        the occurrence of certain events set forth in the Warrant Agreement.

      

      

      Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not
        exercised by the end of such Exercise Period, such Warrants shall become void.

      

      

      Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for
        all purposes have the same effect as though fully set forth at this place.

      

      

      This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

      

      

      This Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to
        conflicts of laws principles thereof.

      

      

      
        
          

      

      	 	
              HUMANCO ACQUISITION CORP.

            
	 	 	 
	 	
              By:

            	 
	 	
              Name:

            	 
	 	
              Title:

            	 
	 	 	 
	 	
              CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent

            
	 	 	 
	 	
              By:

            	 
	 	
              Name:

            	 
	 	
              Title:

            	 

       

      

      
        
          

      

      [Form of Warrant Certificate]

      

      

      [Reverse]

      

      

      The Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive
        shares of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of __________, 2020 (the “Warrant Agreement”),
        duly executed and delivered by the Company to Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant
          Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of
        the Warrant Agent, the Company and the holders (the words “holders” or “holder” meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company.
        Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

      

      

      Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this
        Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together with payment of the Exercise Price as specified in the Warrant
        Agreement (or through “cashless exercise” as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised
        shall be less than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.

      

      

      Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a
        registration statement covering the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating to the shares of Common Stock is current, except through “cashless exercise” as
        provided for in the Warrant Agreement.

      

      

      The Warrant Agreement provides that upon the occurrence of certain events the number of shares of Common Stock issuable upon exercise of the
        Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest in a share of Common Stock, the Company shall, upon
        exercise, round down to the nearest whole number of shares of Common Stock to be issued to the holder of the Warrant.

      

      

      Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by
        legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant
        Certificates of like tenor evidencing in the aggregate a like number of Warrants.

      

      

      Upon due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or
        Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge
        except for any tax or other governmental charge imposed in connection therewith.

      

      

      The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate
        (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall
        be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.

      

      

      
        
          

      

      Election to Purchase

      

      

      (To Be Executed Upon Exercise of Warrant)

      

      

      The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive __________ shares of Common
        Stock and herewith tenders payment for such shares of Common Stock to the order of HumanCo Acquisition Corp. (the “Company”) in the amount
        of $ __________ in accordance with the terms hereof. The undersigned requests that a certificate for such shares of Common Stock be registered in the name of __________, whose address is __________ and that such shares of Common Stock be delivered
        to __________ whose address is __________. If said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of
        such shares of Common Stock be registered in the name of __________, whose address is __________ and that such Warrant Certificate be delivered to __________, whose address is __________.

      

      

      In the event that the Warrant has been called for redemption by the Company pursuant to Section 6.2 of the Warrant Agreement and a holder thereof
        elects to exercise its Warrant pursuant to a Make-Whole Exercise, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section 6.2 of the Warrant Agreement.

      

      

      In the event that the Warrant is a Private Placement Warrant or a Working Capital Warrant that is to be exercised on a “cashless” basis pursuant to
        subsection 3.3.1(c) of the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

      

      

      In the event that the Warrant is to be exercised on a “cashless” basis pursuant to Section
            7.4 of the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section 7.4
        of the Warrant Agreement.

      

      

      In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares
        of Common Stock that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The
        undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of Common Stock. If said number of shares of Common Stock is
        less than all of the shares of Common Stock purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of Common Stock be
        registered in the name of __________, whose address is __________ and that such Warrant Certificate be delivered to __________, whose address is __________.

      

      

      [Signature Page Follows]

      

      

      
        
          

      

      	
              Date:

              

            	 	, 20	 	 
	 	 	
              (Signature)

            
	 	 	 
	 	 	
              (Address)

            
	 	 	 
	 	 	
              (Tax Identification Number)

            
	 	 	 
	
              Signature Guaranteed:

            	 	 

      THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN
        APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 (OR ANY SUCCESSOR RULE) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED).

       

      

      
        
          

      

      EXHIBIT B

      

      

      LEGEND

      

      

      “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT
        BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL
        LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG HUMANCO ACQUISITION CORP. (THE “COMPANY”), HUMANCO ACQUISITION HOLDINGS, LLC AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED HEREBY MAY NOT BE SOLD OR TRANSFERRED
        PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN
        SECTION 2 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

      

      

      SECURITIES EVIDENCED HEREBY AND SHARES OF CLASS A COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO
        REGISTRATION RIGHTS UNDER A REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]